feedback

Course Director

Robert Z. Orlowski, MD, PhD
Robert Z. Orlowski, MD, PhD

The University of Texas MD Anderson Cancer Center
Houston, Texas

Faculty

Shaji Kumar
Shaji Kumar, MD

Mayo Clinic
Rochester, Minnesota

Sagar Lonial
Sagar Lonial, MD, FACP

Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Thomas G. Martin
Thomas G. Martin, MD

University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Accredited by

Penn State College of Medicine

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2018-Jul-03
Expiration Date:2019-Jul-02
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this activity, based on a recent live symposium held at the 2018 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois, top experts in multiple myeloma offer insights from their own practice on how to translate important new evidence into the care of their patients, focusing on the selection of optimized therapy in newly diagnosed patients; the role that newer therapies play in achieving deep, durable, MRD-negative responses; and the clinical implications of ongoing research into newer antibodies and other novel agent classes across many treatment settings.

Upon completion of this activity, participants should be better able to:

  • Summarize new evidence on the treatment role, efficacy, and safety of novel agent classes and next-generation therapeutics in myeloma, including proteasome inhibitors, IMiDs, novel antibodies, immunotherapies, and epigenetic agents, among others
  • Select personalized therapy for patients with newly diagnosed myeloma, including elderly patients, individuals eligible or ineligible for stem-cell transplant, and those requiring maintenance therapy post transplant
  • Recommend therapy for patients with previously treated myeloma, including those with early relapse, refractory disease, or persistent residual disease
  • Manage treatment-related adverse events in patients with myeloma who are receiving therapy with regimens that contain novel components

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, hematologist-oncologists, and other clinicians involved in the management of patients with myeloma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 03, 2018 - July 02, 2019
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator

Robert Z. Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
The University of Texas MD Anderson Cancer Center
Houston, Texas

Robert Z. Orlowski, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for Amgen Inc.; Bristol-Myers Squibb; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Kite Pharma, Inc.; Sanofi-aventis U.S. LLC; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Amgen Inc.; BioTheryX, Inc.; and Spectrum Pharmaceuticals, Inc.
Advisory Board for Amgen Inc.; Bristol-Myers Squibb; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Kite Pharma, Inc.; Sanofi-aventis U.S. LLC; and Takeda Pharmaceutical Company Limited.

Faculty

Shaji Kumar, MD
Professor of Medicine
Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche Ltd-Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Kite Pharma, Inc.; MedImmune; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Sanofi; and Takeda Pharmaceutical Company Limited. Funding for clinical trials goes to Institution.
Advisory Board for AbbVie Inc.; Amgen Inc.; Celgene Corporation; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Kite Pharma, Inc.; MedImmune; Merck & Co., Inc.; Oncopeptides AB; and Takeda Pharmaceutical Company Limited. (No Personal Compensation)

Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Other Financial or Material Support from Consultant and/or Advisor for: Amgen, Inc.; Bristol-Myers Squibb; Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceuticals U.S.A., Inc.

Thomas G. Martin, MD
Clinical Professor of Medicine, Adult Leukemia and Bone Marrow Transplantation Program
Associate Director, Myeloma Program
University of California, San Francisco
Co-Leader, Hematopoietic Malignancies Program
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Thomas G. Martin, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Amgen Inc. and sanofi-aventis.

Medical Directors

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education

Aarati Ranganathan, PhD, has no financial interests/relationships or affiliations in relation to this activity

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6323-19-T.

Providership


This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by educational grants from Adaptive Biotechnologies, Janssen Biotech, Inc., Karyopharm Therapeutics, Inc. and Sanofi Genzyme.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.